Khan, S., Poust, S., Cid, J. D., Fang, Z., Lapointe, D., Ayer, S., Paulick, M., Shrishrimal, S., Merritt, H., Leong, W. I., Hari, K., Heredia, J., Fitzgerald, P., Colmenares, G., Ankoudinova, I., Monroe, L., Hansen, D., Hale, S., Holten-Andersen, L., Perni, R., Bermingham, A., Blair, J., Dhawan, N., Holland, S., Knudsen, T. (2026). Targeting IRF5 with selective covalent oral small molecules attenuates Type I IFN and pro-inflammatory cytokine secretion in human PBMCs and in mice 2309520. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkag141.1558